NABP Joins Representatives of EU Member States and Patient-Safety Organizations to Discuss Falsified Medicines Directive

July 20, 2017

NABP recently joined representatives of 20 European Union (EU) member states and not-for-profit patient safety organizations from the US and Europe in a workshop to discuss the EU Falsified Medicines Directive and the need to raise awareness about the dangers of illegal online drug sellers. The Best Practice Sharing Workshop was hosted by ASOP Global and ASOP EU on June 29, 2017, in Paris, France. “Under the new Falsified Medicines Directive (FMD), beginning in February 2019 every prescription pack in Europe will have a unique identifier data matrix barcode to protect the supply chain from falsified medicines,” ASOP EU Executive Director Mike Isles said in a news release. “In addition, there is also the requirement for each Member State, in co-operation with the EU Health Commission [Directorate General for Health and Food Safety (DG SANTE)] to mount public awareness campaigns on the dangers of falsified medicines and the purpose of a ‘common logo’ . . .” Every genuine pharmacy that sells medicines online is required to display this logo, which is hyperlinked to information from the relevant regulatory body.

Participants also discussed NABP’s .Pharmacy Verified Websites Program, how it works, and how it complements the EU common logo. Both NABP and ASOP EU representatives stressed the need to raise public awareness about buying medication safely online. “The public, patients, and consumers need to know the issues relating to the plethora of illegally operating websites,” Isles said. ASOP EU will issue a report on the various Member State awareness-raising activities to inform the EU Parliament, DG Sante, and other relevant bodies.